Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
Key facts
- Who runs it
- First Affiliated Hospital of Fujian Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 164 people enrolled
- Started
- 7 Aug 2022
- Ended
- 1 May 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transcranial Alternating Current Stimulation
- Record updated
- 12 July 2024
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- for SCA3; Patients with detectable clinical signs and confirmed genetic diagnosis with SCA3; SCA3 patients aged 18 - 80 years; Patients or their family members have informed consent to the study and signed relevant documents; The pre-study ataxia Assessment Score (SARA) ranged from 3 to 30
- for MSA-C; Aged 30-80 years; Diagnosed as clinically determined (Established)MSA-C or clinically Probable MSA-C according to the latest MSA diagnostic criteria; No more than 8 years after diagnosis of MSA-C; Able to walk independently or with assistance; Have a life expectancy of at least 3 years; Women of childbearing age with MSA need to use contraceptive measures
Who cannot take part
- Patients who have concomitant epilepsy
- Patients who have taken other investigational products within 4 weeks before being enrolled in this clinical trial, or patients who are pregnant or breastfeeding
- Patients with a serious cognitive disorder, behavioral disorder, or mental illness
- Patients with a history of seizures, stroke, encephalitis, or other degenerative neurological diseases
- Patients with a serious medical disease; Patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, or moderate or more severe liver disease; Patients with uncontrolled high blood pressure or diabetes
- History of head injury or neurosurgical interventions
- History of any metal in the head (outside the mouth)
- Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line), or any medical pumps
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a longitudinal, triple-blind, randomized-controlled, prospective interventional study assessing patients with cerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy-cerebellar type (MSA-C), to examine the efficacy, safety, and tolerability of transcranial alternating current stimulation (tACS) for up to 3 months.
The 2 groups in the trial
- Real cerebellar tACS for Cerebellar Ataxia (Part Ⅰ: SCA3, Part Ⅱ: MSA-C)Existing treatment, for comparison
Real cerebellar tACS, 70Hz, 2mA (peak to peak), 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
Treatment: Transcranial Alternating Current Stimulation
- Sham cerebellar tACS for Cerebellar Ataxia (Part Ⅰ: SCA3, Part Ⅱ: MSA-C)Sham treatment, for comparison
Device: Sham cerebellar tACS, 10Hz, 2mA (peak to peak) for 40s, and then no current 40min/day (10s ramp up and 10s ramp down), (10 sessions, 5 days/week for 2 weeks)
Treatment: Transcranial Alternating Current Stimulation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Treatment of Transcranial Alternating Current Stimulation(tACS)on Patients With Cerebellar Ataxia: A Randomized, Triple-blind, Parallel-controlled Study
- Publications
- Transcranial alternating current stimulation for treating spinocerebellar ataxia type 3: A randomized controlled trial.Cell reports. Medicine, 2025
- Effects of cerebellar transcranial alternating current stimulation in cerebellar ataxia: study protocol for a randomised controlled trial.Frontiers in neuroscience, 2023
- Record updated
- 12 July 2024